Liver and kidney diseases

Clinics in Liver Disease

Volumn 6, Issue 4, 2002, Pages 981-1011

  Wong, Florence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALCOHOL; ALLOPURINOL; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIRHEUMATIC AGENT; CARBAMAZEPINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FISH OIL; IMMUNOGLOBULIN A; INTERFERON; IRBESARTAN; KETOCONAZOLE; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN DERIVATIVE; PHENYTOIN; PREDNISONE; RIFAMPICIN; SULFONAMIDE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ALCOHOL INTOXICATION; ALCOHOL LIVER CIRRHOSIS; AMYLOIDOSIS; ANALGESIC NEPHROPATHY; CHOLESTASIS; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DRUG MEGADOSE; GRANULOMATOSIS; HELLP SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LIVER DISEASE; LIVER FIBROSIS; LIVER GRANULOMA; LIVER INJURY; LIVER TOXICITY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METABOLIC DISORDER; OBSTRUCTIVE JAUNDICE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PLASMAPHERESIS; PREECLAMPSIA; PREGNANCY; REVIEW; SHOCK; SICKLE CELL ANEMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS HEPATITIS; WILSON DISEASE;

ACETAMINOPHEN; ANEMIA, SICKLE CELL; ANIMALS; ASPIRIN; CHOLESTASIS; CYSTS; GLOMERULONEPHRITIS, IGA; GRANULOMA; HEPATITIS B; HEPATITIS C; HUMANS; KIDNEY DISEASES; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; SHOCK;

EID: 0036867319     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00053-3     Document Type: Review

References (205)

1. Flint A. Clinical report of hydroperitoneum, based on an analysis of 46 cases. Am J Med Sci 1863;45:306-39.
2. Baxter JH, Ashworth CT. Renal lesions in portal cirrhosis. Arch Pathol 1946;70:476-88.
3. Bloodworth JMB, Sommers SC. Cirrhotic glomerulosclerosis: A renal lesion associated with hepatic cirrhosis. Lab Invest 1959;8:962-78.
4. Fisher ER, Hellstrom HR. Membranous and proliferative glomerulohephritis of hepatic cirrhosis. Am J Clin Pathol 1959;32:48-55.
5. Sakaguchi H, Dachs S, Grishman E, Paronetto F, Salomon M, Churg J. Hepatic glomerulosclerosis: An electron microscopic study of renal biopsies in liver diseases. Lab Invest 1965;14:533-45.
6. Nochy D, Callard P, Bellon B, Bariety J, Druet P. Association of overt glomerulonephritis and liver disease: A study of 34 patients. Clin Nephrol 1976;6:422-7.
7. Salomon MI, Sakaguchi H, Churg J, Dachs S, Grishman E, Mautner W, et al. Renal lesions in hepatic disease: A study based on kidney biopsies. Arch Intern Med 1965;115:704-9.
8. Berger J, Yaneva H, Nabarra B. Glomerular changes in patients with cirrhosis of the liver. Adv Nephrol 1977;7:3-14.
9. Bene MC, De Korwin JD, de Ligny BH, Aymard B, Kessler M, Faure GC. IgA nephropathy and alcoholic liver cirrhosis. Am J Clin Pathol 1988;89:769-73.
10. Smith SM, Hoy WE. Frequent association of mesangial glomerulonephritis and alcohol abuse; a study of 3 ethnic groups. Modern Pathol 1989;2:138-43.
11. Wagner J. Drunken driving and renal failure - Do you see a link? Nephrol Dial Transplant 1999;14:1019-20.
12. van de Weil A, Schuurman HJ, Kater L. Immunoglobulin A in alcoholic liver disease. Contrib Nephrol 1984;40:276-82.
13. van Es LA, de Fijter JW, Daha MR. Pathogenesis of IgA nephropathy. Nephrology 1997;3:3-12.
14. Lee FI. Immunoglobulins in viral hepatitis and active alcoholic liver disease. Lancet 1965;2:1043-6.
15. Thompson RA, Carter R, Strokes RP, Geddes AM, Goodall JAD. Serum immunoglobulins, complement levels and autoantibodies in liver disease. Clin Exp Immunol 1973;14:335-46.
16. Morgan MY, Ross M, Ng CM, Adams DM, Thomas HC, Sherlock S. HLA-B8, immunoglobulins, and antibody responses in alcohol-related liver disease. J Clin Pathol 1980;33:488-92.
17. Sancho J, Egido J, Sanchez-Crespo M, Blasco R. Detection of monomeric and polymeric IgA containing immune complexes in serum and kidney from patients with alcoholic liver disease. Clin Exp Immunol 1982;47:327-35.
18. Worthington BS, Meserole L, Syrotuck JA. Effect of daily ethanol ingestion on intestinal permeability to macromolecules. Am J Dig Dis 1978;23:23-32.
19. Amore A, Coppo R, Roccatello D, Piccoli G, Mazzucco G, Gomez-Chiarri M, et al. Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake. Lab Invest 1994;70:68-77.
20. Roccatello D, Picciotto G, Coppo R, Piccoli G, Molino A, Cacace G, et al. Clearance of polymeric IgA aggregates in humans. Am J Kidney Dis 1989;14:354-60.
21. Roccatello D, Picciotto G, Torchio M, Ropolo R, Ferro M, Franceschini R, et al. Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients: The role of asialoglycoprotein receptors. Lab Invest 1993;69:714-23.
22. Floege J, Feehally J. IgA nephropathy: Recent developments. J Am Soc Nephrol 2000;11:2395-403.
23. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: A randomized controlled trial. Lancet 1999;353:883-7.
24. Donadio Jr. JV, Bergstrahl EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil and IgA nephropathy. N Engl J Med 1994;331:1194-8.
25. Dillon JJ. Fish oil therapy for IgA nephropathy: Efficacy and interstudy variability. J Am Soc Nephrol 1997;8:1739-44.
26. Nolin L. Courteau M. Management of IgA nephropathy: Evidence-based recommendations. Kidney Int 1999;70(suppl):S56-62.
27. Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD. Effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. J Hepatol 1987;4:330-6.
28. Gentilini P, Romanelli RG, Villa GL, Maggiore Q, Pesciullesi E, Cappelli G, et al. Effect of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of liver. Gastroenterology 1993;104:588-94.
29. Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, et al. The anti-proteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998;9:2308-17.
30. Vlachogiannakos J, Tang AKW, Patch D, Burroughs AK. Angiotensin converting enzyme inhibitors and angiotensin antagonists as therapy in chronic liver disease. Gut 2001;49:303-8.
31. Girgrah N, Liu P, Blendis LM, Wong F. Hemodynamic sodium handling effects of Losartan, an angiotensin II receptor antagonist, in pre-ascitic cirrhosis. Gut 2000;46:114-20.
32. D'Amico G, Colasanti G, Barbiano di Belgioioso G, Fellin G, Ragni A, Egidi F, Radaelli L, et al. Long-term follow-up of IgA mesangial nephropathy: Clinico-histological study in 374 patients. Semin Nephrol 1987;7:355-8.
33. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991;18:12-9.
34. Ibels LS, Gyory AZ. IgA nephropathy: Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 1994;73:79-102.
35. Pham PT, Pham PC, Wilkinson AH. The kidney in liver transplantation. Clin Liver Dis 2000;4:567-90.
36. Willson RA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997;92:3-17.
37. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995;108:157-64.
38. Paydas S, Seyrek N, Gonlusen G, Sagliker Y. The frequencies of hepatitis B virus markers and hepatitis C virus antibody in patients with glomerulonephritis. Nephron 1996;74:617-9.
39. Combes B, Shorey J, Barrera A, Shastny P, Eigenbrodt EH, Hull AR, et al. Glomerulonephritis with deposition of Australian antigen-e antibody complexes in glomerular basement membrane. Lancet 1971;2:234-7.
40. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: Clinical, immunopathogenic and therapeutic considerations. Kidney Int 1990;37:663-76.
41. Lai KN, Lai FM, Chan KW, Chow CB, Tong KL, Vallance-Owen J. The clinico-pathological features of hepatitis B virus associated glomerulonephritis. Q J Med 1987;63:323-33.
42. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990;37:663-76.
43. de Man RA, Schalm SW, van der Heijden AJ, ten Kate FW. Wolff ED, Heijtink RA. Improvement of hepatitis-associated glomerulonephritis after anti-viral combination therapy. J Hepatol 1989;8:367-72.
44. Lin CY. Treatment of hepatitis B-associated membranous nephropathy with recombinant α-interferon. Kidney Int 1995;47:225-30.
45. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon-alfa. Gastroenterology 1995;109:540-6.
46. Lok ASF. Antiviral therapy of the Asian patient with chronic hepatitis B. Semin Liver Dis 1993;13:360-6.
47. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: The case against autoimmune intervention in pathogenesis. J Autoimmun 2001;16:269-74.
48. Matsumori A. Symposium on clinical aspects in hepatitis virus infection. V. Clinical practice of hepatitis: Myocardial diseases, nephritis, and vasculitis associated with hepatitis virus. Intern Med 2001;40:182-4.
49. Erhardt A, Sagir A, Guillevin L, Neuen-Jacob E, Haussinger D. Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, α-interferon and lamivudine. J Hepatol 2000;33:677-83.
50. Wicki J, Olivieri J, Pizzolato G, Sarasin F, Guillevin L, Dayer JM, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon α. Rheumatology 1999;38:183-5.
51. Gupta S, Piraka C, Jaffe M. Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B. N Engl J Med 2001;344:1645-6.
52. McMahon BJ, Alberts SR, Weinwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae: Prospective study in 1400 hepatitis B surface antigen-positive Alaskan native carriers. Arch Intern Med 1990;150:1051-4.
53. Lohr H, Goergen B, Weber W, Godderz W, Meyer zum Buschenfelde KH, Gerken G. Mixed cryoglobutinemia type II in chronic hepatitis B associated with HBe-minus HBV mutant: Cellular immune reactions and response to interferon treatment. J Med Virol 1995;44:330-5.
54. Rollino C, Roccatello D, Giachino O, Basolo B, Piccoli G. Hepatitis C virus infection and membranous glomerulonephritis. Nephron 1991;59:319-20.
55. Komatsuda A, Imai H, Wakui H, Hamai K, Ohtani H, Kodama T, et al. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Int J Med 1996;35:529-33.
56. Fabrizi F, Pozzi C, Farina M, Dattolo P, Lunghi G, Badalamenti S, et al. Hepatitis C virus infection and acute or chronic glomerulonephritis: An epidemiological and clinical appraisal. Nephrol Dial Transplant 1998;13:1991-7.
57. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999;106:347-54.
58. Gopalani A, Ahuja TS. Prevalence of glomerulopathies in autopsies of patients infected with the hepatitis C virus. Am J Med Sci 2001;322:57-60.
59. Yamabe H, Johnson RJ, Gretch DR, Fukushi K, Osama H, Miyata M, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995;6:220-3.
60. Garcia-Valdecasas J, Bernal C, Garcia F, Cerezo S, Umana WO, von Albertini B, et al. Epidemiology of hepatitis C virus infection in patients with renal disease. J Am Soc Nephrol 1994;5:186-92.
61. Mitwalli A, Al-Mohaya S, Al Wakeel J, el Gamal H, Rotimi V, al-Zeben A. Hepatitis C in chronic renal failure patients. Am J Nephrol 1992;12:288-91.
62. Okada K, Takishita Y, Shimomura H, Tsuji T, Miyamura T, Kuhara T, et al. Detection of hepatitis C virus core protein in the glomeruli of patients with membranous glomerulonephritis. Clin Nephrol 1996;45:71-6.
63. Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, et al. Cryoglobulinemia in chronic liver disease: Role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291-300.
64. Davis CL, Gretch DR, Carithers RL. Hepatitis C virus in renal disease. Curr Opin Nephrol Hypertens 1994;3:164-73.
65. Horikoshi S, Okada T, Shirato I, Inokuchi S, Ohmuro H, Tomino Y, et al. Diffuse proliferative glomerulonephritis with hepatitis C-like particles in paramesangial dense deposits in a patient with chronic hepatitis C viral hepatitis. Nephron 1993;64:482-4.
66. Schifferli JA, French LE, Tissot JD. Hepatitis C virus infection, cryoglobutinemia, and glomerulonephritis. Adv Nephrol 1995;24:107-29.
67. Pawlotsky J, Ben Yahia M, Andre C, Voisin MC, Intrata L, Roudot-Thoraval F, et al. Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994;19:841-8.
68. Okada K, Takishita Y, Shimomura H, Tsuji T, Miyamura T, Kuhara T, et al. Detection of hepatitis C virus core protein in the glomeruli of patients with membranous glomerulonephritis. Clin Nephrol 1996;45:71-6.
69. Misiani R, Bellavista P, Fenili D, Vicari O, Marshesi S, Sironi PL, et al. Interferon α-2a therapy in cryoglobulinemia associated with hepatitis virus. N Engl J Med 1994;330:751-6.
70. Izopet J, Rostaing L, Moussion L, Alric L, Dubois M, That HT, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon α therapy. J Clin Infect Dis 1997;176:1614-7.
71. Yamabe H, Johnston R, Gretch D, Osawa H, Inuma H, Sasaki T, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon α. Am J Kidney Dis 1995;25:67-9.
72. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-α. J Rheumatol 2000;27:2172-8.
73. Quigg RJ, Brathwaite M, Gardner DF, Gretch DR, Ruddy S. Successful cyclophosamide treatment of cryoglobulinemic and membranoproliferative glomerulonephritis associated with hepatitis C infection. Am J Kidney Dis 1995;25:798-800.
74. Reed MJ, Alexander GJM, Thiru S, Smith KGC. Hepatitis C associated glomerulonephritis - A novel therapeutic approach. Nephrol Dial Transplant 2001;16:869-71.
75. Geltner D. Therapeutic approaches in mixed cryoglobulinemia. Springer Semin Immunopathol 1998;10:103-13.
76. Brunkhorst R, Klein V, Koch K. Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C. Nephron 1996;72:465-7.
77. Mancini C, Gaeta A, Lorino G, Filadoro F, Marinucci G, Bachetoni A, et al. α interferon therapy in patients with hepatitis infection undergoing organ transplantation. Transplant Proc 1989;21:2429-30.
78. Chan TM, Lok ASF, Cheng IKP, Ng IO. Chronic hepatitis C after renal transplantation: Treatment α-interferon. Transplantation 1993;56:1095-8.
79. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994;45:1507-9.
80. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon α 2b for chronic hepatitis C. Nephron 1996;74:512-6.
81. Hardy JD. Renal failure in the jaundiced patient. Surgery 1989;105:238-9.
82. Masumoto T, Masuoka S. Kidney function in the severely jaundiced dog. Am J Surg 1980;140:426-30.
83. Thompson JN, Edwards WH, Winearls CG, Blenkharn JI, Benjamin IS, Blumgart LH. Renal impairment following biliary tract surgery. Br J Surg 1987;74:843-7.
84. Blamey SL, Fearon KC, Gilmour WH, Osborne DH, Carter DC. Prediction of risk in biliary surgery. Br J Surg 1983;70:535-8.
85. Sitges-Serra A, Carulla X, Piera C, Martinez-Rodenas F, Franch G, Pereira J, et al. Body water compartments in patients with obstructive jaundice. Br J Surg 1992;79:553-6.
86. Green J, Beyar R, Sideman S, Mordechovitz D, Better OS. The "jaundiced heart": A possible explanation for postoperative shock in obstructive jaundice. Surgery 1986;100:14-20.
87. Padillo J, Puente J, Gomez M, Dios F, Naranjo A, Juan A, et al. Improved cardiac function in patients with obstructive jaundice after internal biliary drainage. Ann Surg 2001;234:652-6.
88. Gallardo JM, Padillo J, Martin-Malo A, Mino G, Pera C, Sitges-Serra A. Increased plasma levels of atrial natriuretic peptide and endocrine markers of volume depletion in patients with obstructive jaundice. Br J Surg 1998;85:28-31.
89. Dawiskiba J. The role of endotoxaemia in the development of renal disorders in experimental obstructive jaundice in rats. HPB Surg 1996;10:7-10.
90. Bomzon A, Holt S, Moore K. Bile acids, oxidative stress, and renal function in biliary obstruction. Semin Nephrol 1997;17:549-62.
91. Orlinsky M, Shoemaker W, Reis ED, Kerstein MD. Current controversies in shock and resuscitation. Surg Clin North Am 2001;81:1217-62.
92. Gubern JM, Sancho JJ, Simo J, Sitges-Serra A. A randomized trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice. Surgery 1988;103:39-44.
93. Lucena MI, Andrade RJ, Cabello MR, Hidalgo R, Gonzalez-Correa JA, Sanchez de la Cuesta F. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol 1995;22:189-96.
94. Lucena MI, Gonzalez-Correa JA, Andrade RJ, Ibanez J, Torres D, Sanchez de la Cuesta F. Enhanced gentamicin nephrotoxicity after experimental biliary obstruction in rats. Pharmacol Toxicol 1989;65:352-6.
95. Lucena MI, Andrade RJ. Extrahepatic cholestasis as a distinct factor predisposing to gentamicin nephrotoxicity. Am J Med 1990;85:698-9.
96. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: Frequency and relation to prognosis. Hepatology 1999;29:822-9.
97. Heathcote J. The clinical expression of primary biliary cirrhosis. Semin Liver Dis 1997;1:23-33.
98. Whitehead EM, Daly JG, Hayes JR. Renal tubular acidosis in association with Sjogren's syndrome, primary biliary cirrhosis and coeliac disease. Irish J Med Sci 1987;156:124-5.
99. Kodama T, Imai H, Wakui H, Ohtani H, Komatsuda A, Miura AB. Tubulointerstitial nephritis with renal tubular acidosis and asymptomatic primary biliary cirrhosis accompanied by antibody to a 52-kDa mitochondrial protein alone. Clin Nephrol 1996;45:401-5.
100. Davidson BK, Haslock I. Osteomalacia secondary to renal tubular acidosis masquerading as primary biliary cirrhosis. Rheumatology 2000;39:1428-9.
101. Izumi N, Hasumura Y, Takeuchi J. Hypouricemia and hyperuricosuria as expressions of renal tubular damage in primary biliary cirrhosis. Hepatology 1983;3:719-23.
102. Michel DM, Kelly CJ. Acute interstitial nephritis. J Am Soc Nephrol 1998;9:506-15.
103. Fulop M, Sternlieb I, Scheinberg IH. Defective urinary acidification in Wilson's disease. Ann Intern Med 1968;68:770-7.
104. Sulochana G, Viswanathan J. Wilson's disease with associated diabetes mellitus presenting as renal tubular acidosis. J Assoc Physicians India 1982;30:405-7.
105. Wilson DM, Goldstein NP. Bicarbonate excretion in Wilson's disease (hepatolenticular degeneration). Mayo Clinic Proc 1974;49:394-400.
106. Itami N, Akutsu Y, Tochimaru H, Takekoshi Y. Hypercalciuria and nephrolithiasis in Wilson disease. Eur J Pediatr 1989;149:145.
107. Wiebers DO, Wilson DM, McLeod RA, Goldstein NP. Renal stones in Wilson's disease. Am J Med 1979;67:249-54.
108. Fagan E, Wannan G. Reducing paracetamol overdoses. BMJ 1996;313:1417-8.
109. Schiodt FV, Atillasoy E, Shakil AO, Schiff ER, Caldwell C, Kowdley KV, et al. Etiology and prognosis for 295 patients with acute liver failure. Liver Transpl Surg 1999;5:29-34.
110. McCormick PA, Casey P, Barry P, Laffoy M, Treacy J. Delays in administration of acetylcysteine in paracetamol overdose. Ir Med J 2000;93:77-8.
111. Gow PJ, Smallwood RA, Angus PW. Paracetamol overdose in a liver transplantation centre: An 8-year experience. J Gastroenterol Hepatol 1999;14:817-21.
112. Yamada T. Covalent binding theory for acetaminophen hepatotoxicity. Gastroenterology 1983;85:202-3.
113. McClain CJ, Price S, Barve S, Devalarja R, Shedlofsky S. Acetaminophen hepatotoxicity: An update. Curr Gastroenterol Rep 1999;1:42-9.
114. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
115. Eguia L, Materson BJ. Acetaminophen-related acute renal failure without fulminant liver failure. Pharmacotherapy 1997;17:363-70.
116. Ammenti A, Ferrante R, Spagna A. Renal impairment without hepatic damage after acetaminophen overdose. Pediatr Nephrol 1999;13:271-2.
117. Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990;335:1572-3.
118. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, et al. Acetaminophen, aspirin and chronic renal failure. N Engl J Med 2001;345:1801-8.
119. Segasothy M, Suleiman AB, Puvaneswary M, Rohana A. Paracetamol; a cause of analgesic nephropathy and end stage renal disease. Nephron 1988;50:50-4.
120. Buckalew Jr VM. Habitual use of acetaminophen as a risk factor for chronic renal failure: A comparison with phenacetin. Am J Kidney Dis 1996;28(suppl):S7-13.
121. Seaman WE, Plotz PH, Ishak KG. Aspirin-induced hepatotoxicity in patients with rheumatoid arthritis or systemic lupus erythematosus. Arthritis Rheum 1974;17:325.
122. Koppes GM, Arnett FC. Salicylate hepatotoxicity. Postgrad Med 1974;56:193-5.
123. Miller MH, Urowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. Q J Med 1984;53:401-9.
124. O'Gorman T, Koff RS. Salicylate hepatitis. Gastroenterology 1977;72:726-8.
125. Monto AS. The disappearance of Reye's syndromem - A public health triumph. N Engl J Med 1999;340:1423-4.
126. Valencia AM, Quevedo FW, Quintos LS. Reye's syndrome: Not of historical interest only. Pediatr Infect Dis J 1997;16:1011-2.
127. Lomoy W, Becaus I, Billiouw JM, Sierens L. Analgesic nephropathy: Clinical features and pathogenesis. Original data on the incidence and prevalence in a single renal unit. Acta Clin Belg 1998;53:311-8.
128. Duggin GG. Combination analgesic-induced kidney disease: The Australian experience. Am J Kidney Dis 1996;28(suppl):S39-47.
129. Wolf JL. Liver disease in pregnancy. Med Clin North Am 1996;80:1167-87.
130. Schorr-Lesnick B, Lebovics E, Dworkin B, Rosenthal WS. Liver diseases unique to pregnancy. Am J Gastroenterol 1991;86:659-70.
131. Barron WM. The syndrome of preeclampsia. Gastroenterol Clin North Am 1992;21:851-72.
132. Riely CA. Liver disease in the pregnant patient. Am J Gastroenterol 1999;947:1728-32.
133. Barton JR, Sibai BM. Care of the pregnancy complicated by HELLP syndrome. Obstet Gynecol Clin North Am 1991;18:165-79.
134. Abdi S, Cameron IC, Nakielny RA, Majeed AW. Spontaneous hepatic rupture and matemal death following an uncomplicated pregnancy and delivery. BJOG 2001;108:431-3.
135. Knapen MF, van Altena AM, Peters WH, Merkus HM, Jansen JB, Steegers EA. Liver function following pregnancy complicated by the HELLP syndrome. BJOG 1998;105:1208-10.
136. Sakala EP, Moore WD. Successful term pregnancy after previous pregnancy with ruptured liver. Obstet Gynecol 1986;68:124-6.
137. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332-42.
138. Calvet J, Grantham JJ. The genetics and physiology of polycystic kidney disease. Semin Nephrol 2001;21:107-23.
139. Wilson PD. Polycystin: New aspects of structure, function, and regulation. J Am Soc Nephrol 2001;12:834-45.
140. Murcia NS, Woychik RP, Avner ED. The molecular biology of polycystic kidney disease. Pediatr Nephrol 1998;12:721-6.
141. Milutinovic J, Fialkow PJ, Agodoa LY, Phillips LA, Rudd TG, Sutherland S. Clinical manifestation of autosomal dominant polycystic kidney disease in patients older than 50 years. Am J Kidney Dis 1990;15:237-43.
142. Jeyarajah DR, Gonwa TA, Testa G, Abbasoglu O, Goldstein R, Husberg BS, et al. Liver and kidney transplantation for polycystic disease. Transplantation 1998;66:529-32.
143. Desmet VJ. Congenital diseases of intrahepatic bile ducts: Variations on the theme ductal plate malformation. Hepatology 1992;16:1069-83.
144. De Vos M, Barbier F, Cuvelier C. Congenital hepatic fibrosis. J Hepatol 1988;6:222-8.
145. Huang HY, Huang HY, Chen WJ. Non-syndromic association of congenital hepatic fibrosis and bilateral cystic renal dysplasia. J Formos Med Assoc 2000;11:863-5.
146. Forbes A, Murray-Lyon IM. Cystic diseases of the liver and biliary tract. Gut 1991;(suppl):S116-22.
147. Moreno-Merlo F, Wanless IR, Shimamatsu K, Sherman M, Greig P, Chiasson D. The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Hepatology 1997;26:554-60.
148. Ishak KG. Sarcoidosis of the liver and bile duct. Mayo Clin Proc 1998;73:467-72.
149. Mueller S, Boehme MW, Hofmann WJ, Stremmel W. Extrapulmonary sarcoidosis primarily diagnosed in the liver. Scand J Gastroenterol 2000;35:1003-8.
150. Casavilla FA, Gordon R, Wright HI, Gavaler JS, Starzl TE, Van Thiel DH. Clinical course after liver transplantation in patients with sarcoidosis. Ann Intern Med 1993;118:856-65.
151. Adams JS, Singer FR, Gacad MA, Sharma OP, Hayes MJ, Vouros P, et al. Isolation and structural identification of 1,25-dihydroxyvitamin D produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab 1985;60:960-6.
152. Johns CJ. The clinical management of sarcoidosis: A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999;78:65-111.
153. Utas C, Dogukan A, Patiroglu TE, Oymak S, Oymak O. Granulomatous interstitial nephritis in extrapulmonary sarcoidosis. Clin Nephrol 1999;51:252-4.
154. Sheffield EA. Pathology of sarcoidosis. Clin Chest Med 1997;18:741-53.
155. Campbell F, Douglas-Jones AG. Sarcoid-like granulomas in primary renal cell carcinoma. Sarcoidosis 1993;10:128-31.
156. Moder KG, Litin SC, Gaffey TA. Renal cell carcinoma associated with sarcoidlike tissue reaction. Mayo Clin Proc 1990;65:1498-501.
157. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: A review. Ann Pharmacother 1993;27:337-43.
158. Braden GL, Warzynski MJ, Golightly M, Ballow M. Cell-mediated immunity in allopurinolinduced hypersensitivity. Clin Immunol Immunopathol 1994;70:145-51.
159. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155:2285-90.
160. Schwarz A, Perez-Canto A. Nephrotoxicity of antiinfective drugs. Int J Clin Pharmacol Ther 1998;36:164-7.
161. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type I (insulin-dependent) diabetes: An epidemiological study. Diabetologia 1983;25:496-501.
162. Hostetter TH. Hypertrophy and hyperfunction of the diabetic kidney. J Clin Invest 2001;107:161-2.
163. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001;38:S100-6.
164. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: A nephrologist's perspective. Am J Kidney Dis 2000;35:365-80.
165. Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation end products are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000;37:87-92.
166. The Diabetes Control and Complications Research Group. The effects of intensive insulin treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
167. Kshirsagar AV. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000;35:695-707.
168. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type I diabetic nephropathy: Collaborative Study Group. Am J Kidney Dis 1999;34:809-17.
169. DCCT Research Group. The effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-20.
170. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am 1999;13:1211-33.
171. Browning MJ, Banks RA, Tribe CR, Hollingworth P, Kingswood C, Mackenzie JC, et al. 1. Ten years' experience of an amyloid clinic - A clinicopathological survey. Q J Med 1985;54:213-27.
172. Schena FP, Pannarale G, Carbonara MC. Clinical and therapeutic aspects of renal amyloidosis. Nephrol Dial Transplant 1996;11(suppl):63-8.
173. Sasatomi Y, Kiyoshi Y, Uesugi N, Hisano S, Takebayashi S. Prognosis of renal amyloidosis: A clinicopathological study using cluster analysis. Nephron 2001;87:42-9.
174. Espinosa G, Font J, Garcia-Pagan JC, Tassies D, Reverter JC, Cervantes F, et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome. Medicine (Baltimore) 2001;80:345-54.
175. Berden JHM. Lupus nephritis. Kidney Int 1997;52:538-58.
176. Huong DLT, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: A study of 180 patients from a single centre. Medicine (Baltimore) 1999;78:148-66.
177. D'Agati VD. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogrens syndrome, and rheumatoid arthritis. In: Jennette CJ, Olson L, Schwartz MM, Silva F, editors. Pathology of the Kidney. 5th Editon. Philadelphia: Lippincott-Raven; 1998. p. 541-624.
178. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis: The importance of hypertension and smoking. Arch Intern Med 1992;152:2082-8.
179. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center: Causes of death. J Rheumatol 1995;22:1259-64.
180. Johnson CS, Omata M, Tong MJ, Simmons Jr. JF, Weiner J, Tatter D. Liver involvement in sickle cell disease. Medicine (Baltimore) 1985;64:349-56.
181. Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy. Hepatology 2001;33:1021-8.
182. Sheehy TW. Sickle cell hepatopathy. South Med J 1977;70:533-8.
183. Saltzman JR, Johnston DE. Sickle cell crisis and cocaine hepatotoxicity. Am J Gastroenterol 1992;87:1661-4.
184. Shao SH, Orringer EP. Sickle cell intrahepatic cholestasis: Approach to a difficult problem. Am J Gastroenterol 1995;90:2048-50.
185. Schubert TT. Hepatobiliary system in sickle cell disease. Gastroenterology 1986;90:2013-21.
186. Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M, et al. A comparison of conservative and aggressive transfusion regimens in the peri-operative management of sickle cell disease: The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995;333:206-13.
187. DeVault KR, Friedman LS, Westerberg S, Martin P, Hosein B, Ballas SK. Hepatitis C in sickle cell anemia. J Clin Gastroenterol 1994;18:206-9.
188. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Grittith PM, Nienhius AW, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-5.
189. Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: A randomized, double-blind study of the dose-response relationship. J Lab Clin Med 1993;122:48-54.
190. Van Eps LWS, de Jong PE. Sickle cell disease. In: Schrier RW, Gottschalk CW, editors. Diseases of the Kidney. Boston: Little, Brown; 1997. p. 561-90.
191. Baron BW, Mick R, Baron JM. Hematuria in sickle cell anemia - Not always benign: Evidence for excess frequency of sickle cell anemia in African Americans with renal cell carcinoma. Acta Haematol 1994;92:119-22.
192. Sorborio P, Scheinman JI. Sickle cell nephropathy. J Am Soc Nephrol 1999;10:187-92.
193. Powars DR, Elliot-Mills DD, Chan L, Hiti AL, Opas LM, Johnson C. Chronic renal failure in sickle cell disease: Risk factors, clinical course, and mortality. Ann Intern Med 1991;115:614-20.
194. Parker CJ, Lee GR. Paroxysmal nocturnal hemoglobinuria. In: Lee GR, Foerster J, Lukens J, et al, editors. Wintrobe's Clinical Hematology. Baltimore: Williams & Wilkins; 1999. p. 1264-88.
195. Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rosec C, et al. Paroxysmal nocturnal haemoglobinuria: Long term follow-up and prognostic factors. Lancet 1996;348:573-7.
196. Blum SF, Sullivan JM, Gardner FH. The exacerbation of hemolysis in paroxysmal nocturnal hemoglobinuria by strenuous exercise. Blood 1967;30:513-7.
197. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-8.
198. Tomizuka H. Portal vein thrombosis in paroxysmal nocturnal haemoglobinuria. Acta Haematol 1999;101:149-52.
199. Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS, et al. Hepatic outflow obstruction (Budd-Chiari Syndrome): Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994;73:21-36.
200. Henrion J, Descamps O, Luwaert R, Schapira M, Parfonry A, Heller F. Hypoxic hepatitis in patients with cardiac failure: Incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol 1994;21:696-703.
201. Seeto RK, Rockey D. Ischemia hepatitis: Clinical presentation and pathogenesis. Am J Med 2000;109:109-13.
202. Groeneveld ABJ, Thijs LG. Hypovolemic shock. In: Parillo JE, Bone RC, editors. Critical Care Medicine: Principles of Diagnosis and Management. St. Louis: Mosby; 1995. p. 387-418.
203. Kribben A, Edelstein CL, Schrier RW. Pathophysiology of acute renal failure. J Nephrol 1999;12(suppl):S142-51.
204. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systemic review of randomized trials. BMJ 1998;316:961-4.
205. Barretti P, Soares VA. Acute renal failure: Clinical outcome and causes of death. Renal Fail 1997;19:153-257.